Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Pl...

por Strojek, Krzysztof, Yoon, Kun-Ho, Hruba, Veronika, Sugg, Jennifer, Langkilde, Anna Maria, Parikh, Shamik
Publicado 2014

SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m(2) in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes

por Mathieu, Chantal, Dandona, Paresh, Phillip, Moshe, Xu, John, Thorén, Fredrik, Scheerer, Markus, Langkilde, Anna-Maria
Publicado 2019

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial

por Vart, Priya, Jongs, Niels, Wheeler, David C., Heerspink, Hiddo J. L., Langkilde, Anna Maria, Chertow, Glenn M.
Publicado 2023

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

por Kaku, Kohei, Maegawa, Hiroshi, Tanizawa, Yukio, Kiyosue, Arihiro, Ide, Yumiko, Tokudome, Takuto, Hoshino, Yuji, Yang, Jisin, Langkilde, Anna Maria
Publicado 2014

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

por Fioretto, Paola, Del Prato, Stefano, Buse, John B., Goldenberg, Ronald, Giorgino, Francesco, Reyner, Daniel, Langkilde, Anna Maria, Sjöström, C. David, Sartipy, Peter
Publicado 2018

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure

por BJORNSTAD, PETTER, GREASLEY, PETER J., WHEELER, DAVID C., CHERTOW, GLENN M., LANGKILDE, ANNA MARIA, HEERSPINK, HIDDO J.L., VAN RAALTE, DANIËL H.
Publicado 2021

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical...

por Araki, Eiichi, Watada, Hirotaka, Uchigata, Yasuko, Tomonaga, Osamu, Fujii, Hitomi, Ohashi, Hiroshi, Okabe, Tadashi, Asano, Michiko, Thoren, Fredrik, Kim, Hyosung, Yajima, Toshitaka, Langkilde, Anna Maria
Publicado 2019

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D...

por Koshino, Akihiko, Neuen, Brendon L., Jongs, Niels, Pollock, Carol, Greasley, Peter J., Andersson, Eva-Marie, Hammarstedt, Ann, Karlsson, Cecilia, Langkilde, Anna Maria, Wada, Takashi, Heerspink, Hiddo J.L.
Publicado 2023

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial

por Chertow, Glenn M., Correa‐Rotter, Ricardo, Vart, Priya, Jongs, Niels, McMurray, John J. V., Rossing, Peter, Langkilde, Anna Maria, Sjöström, C. David, Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J. L.
Publicado 2023

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

por Heerspink, Hiddo J L, Stefansson, Bergur V, Chertow, Glenn M, Correa-Rotter, Ricardo, Greene, Tom, Hou, Fan-Fan, Lindberg, Magnus, McMurray, John, Rossing, Peter, Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C
Publicado 2020

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study...

por Kosiborod, Mikhail, Berwanger, Otavio, Koch, Gary G., Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Javaheri, Ali, Ambery, Philip, Gasparyan, Samvel B., Buenconsejo, Joan, Sjöström, C. David, Langkilde, Anna Maria, Oscarsson, Jan, Esterline, Russell
Publicado 2021

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

por Provenzano, Michele, Jongs, Niels, Vart, Priya, Stefánsson, Bergur V., Chertow, Glenn M., Langkilde, Anna Maria, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J.L.
Publicado 2021

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

por Beernink, Jelle M., Persson, Frederik, Jongs, Niels, Laverman, Gozewijn D., Chertow, Glenn M., McMurray, John J.V., Langkilde, Anna Maria, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J.L.
Publicado 2023

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

por Heerspink, Hiddo J L, Sjöström, C David, Jongs, Niels, Chertow, Glenn M, Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J V, Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur V, Toto, Robert D, Langkilde, Anna Maria, Wheeler, David C
Publicado 2021

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

por Persson, Frederik, Rossing, Peter, Vart, Priya, Chertow, Glenn M., Hou, Fan Fan, Jongs, Niels, McMurray, John J.V., Correa-Rotter, Ricardo, Bajaj, Harpreet S., Stefansson, Bergur V., Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J.L.
Publicado 2021

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

por Curtain, James P, Docherty, Kieran F, Jhund, Pardeep S, Petrie, Mark C, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Bengtsson, Olof, Langkilde, Anna Maria, Sjöstrand, Mikaela, Solomon, Scott D, McMurray, John J V
Publicado 2021

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic...

por Wheeler, David C, Jongs, Niels, Stefansson, Bergur V, Chertow, Glenn M, Greene, Tom, Hou, Fan Fan, Langkilde, Anna Maria, McMurray, John J V, Rossing, Peter, Nowicki, Michal, Wittmann, István, Correa-Rotter, Ricardo, Sjöström, C David, Toto, Robert D, Heerspink, Hiddo J L
Publicado 2021

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial

por Solomon, Scott D., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Lindholm, Daniel, Wilderäng, Ulrica, Öhrn, Fredrik, Claggett, Brian, Langkilde, Anna Maria, Petersson, Magnus, McMurray, John J.V.
Publicado 2021

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial

por Waijer, Simke W., Vart, Priya, Cherney, David Z. I., Chertow, Glenn M., Jongs, Niels, Langkilde, Anna Maria, Mann, Johannes F. E., Mosenzon, Ofri, McMurray, John J. V., Rossing, Peter, Correa-Rotter, Ricardo, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J. L.
Publicado 2022

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

por Berg, David D., Wiviott, Stephen D., Scirica, Benjamin M., Zelniker, Thomas A., Goodrich, Erica L., Jarolim, Petr, Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Braunwald, Eugene, Sabatine, Marc S., Morrow, David A.
Publicado 2021